Continued use of low-dose aspirin may lower pancreatic cancer risk

The longer a person took low-dose aspirin, defined as a dose of 75 to 325 mg of aspirin per day and usually taken as a form of cardiovascular disease prevention, the lower his or her risk for developing pancreatic cancer, according to a study recently published in Cancer Epidemiology, Biomarkers & Prevention. Men and women who took low-dose aspirin regularly had 48 percent reduction in their risk for developing pancreatic cancer. Protection against pancreatic cancer ranged from 39 percent reduction in risk for those who took low-dose aspirin for six years or less, to 60 percent reduction in risk for those who took low-dose aspirin for more than 10 years.

http://www.sciencedaily.com/releases/2014/06/140626101700.htm

Aspirin can reduce colorectal cancer risks for those with specific gene, study shows

Researchers have found that regular use of Aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) may lower an individual's risk for colorectal cancer among individuals who have a high concentration of a DNA product called 15-PGDH in their colons. Researchers found that people who had high levels of 15-PGDH in their colons and took Aspirin reduced their risk by nearly 50%, while regular asprin use had no benefit for those with low levels of 15-PGDH.